Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics—CheckMate 908

BACKGROUND: Therapeutic options are limited in pediatric CNS malignancies. CheckMate 908 (NCT03130959) is an open-label, sequential-arm, phase 1b/2 study investigating nivolumab (NIVO) and NIVO + ipilimumab (IPI) in pediatric patients with high-grade CNS malignancies. METHODS: Patients (N = 166) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunkel, Ira J, Doz, François, Foreman, Nicholas K, Hargrave, Darren, Lassaletta, Alvaro, André, Nicolas, Hansford, Jordan R, Hassall, Tim, Eyrich, Matthias, Gururangan, Sridharan, Bartels, Ute, Gajjar, Amar, Howell, Lisa, Warad, Deepti, Pacius, Misena, Tam, Rachel, Wang, Yu, Zhu, Li, Cohen, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Pediatric Neuro-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398811/
https://www.ncbi.nlm.nih.gov/pubmed/36808285
http://dx.doi.org/10.1093/neuonc/noad031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398811/
https://www.ncbi.nlm.nih.gov/pubmed/36808285
http://dx.doi.org/10.1093/neuonc/noad031

Ejemplares similares